Fig. 6

iCAF score correlate with immunotherapy response. a Kaplan–Meier plots showing the prognostic value of iCAF score in the melanoma immunotherapy cohorts. P-values were calculated by log-rank test. b Percentage of anti − PD1 therapy response among melanoma patients with high and low iCAF scores. Statistical analysis was performed using Fisher's exact test. c Percentage of anti − CTLA − 4 therapy response among melanoma patients with high and low iCAF scores. Statistical analysis was performed using Fisher's exact test. d Heatmap showing immune modulators in melanoma patients with high and low iCAF scores. From left to right: mRNA expression (median-normalized expression levels of immune modulators); expression versus methylation (Spearman correlation between expression of immune modulators and DNA methylation beta-values); amplification frequency (difference in the proportion of immune modulators amplifications between patients with high or low iCAF scores and the proportion of immune modulators amplifications in all patients.); and the deletion frequency (as amplifications). e Boxplot showing the comparison of immune related scores in melanoma patients with high and low iCAF scores. Statistical analysis was performed using Wilcoxon rank-sum tests; *P < 0.05, **P < 0.01, ***P < 0.001